Dashboard
Manage Tickers

CLDXCelldex Therapeutics, Inc.

Nasdaq celldex.com


$ 32.71 $ 0.65 (2.03 %)    

Thursday, 08-Aug-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 449.23 $ 13.30 (3.06 %)
DIA $ 395.05 $ 6.75 (1.74 %)
SPY $ 531.28 $ 11.99 (2.31 %)
TLT $ 95.30 $ -0.59 (-0.62 %)
GLD $ 224.00 $ 3.46 (1.57 %)
$ 32.71
$ 32.69 x 100
$ 32.74 x 106
-- - --
$ 22.11 - $ 53.18
467,242
na
2.16B
$ 0.85
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-06-2024 03-31-2024 10-Q
3 02-26-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-29-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-06-2020 03-31-2020 10-Q
19 03-26-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 03-07-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-07-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-08-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-14-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-08-2016 06-30-2016 10-Q
34 05-05-2016 03-31-2016 10-Q
35 02-23-2016 12-31-2015 10-K
36 11-05-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
38 04-29-2015 03-31-2015 10-Q
39 02-24-2015 12-31-2014 10-K
40 11-05-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

celldex-therapeutics-q2-eps-054-beats-060-estimate-sales-250m-beat-82043k-estimate
Celldex Therapeutics Q2 EPS $(0.54) Beats ...
08/08/2024 21:08:05

Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of ...

why-merck-shares-are-trading-lower-by-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Merck Shares Are Trading Lower By 10%?...
07/30/2024 17:53:26

cantor-fitzgerald-reiterates-overweight-on-celldex-therapeutics-maintains-67-price-target
Cantor Fitzgerald Reiterates Overweight on...
07/30/2024 13:58:17

Cantor Fitzgerald analyst Kristen Kluska reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and maintains $67 p...

lattice-semiconductor-posts-weak-q2-results-joins-symbotic-woodward-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
Lattice Semiconductor Posts Weak Q2 Result...
07/30/2024 12:28:51

hc-wainwright--co-reiterates-buy-on-celldex-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Cell...
07/30/2024 11:46:09

HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $80 ...

why-f5-shares-are-trading-higher-by-over-14-here-are-20-stocks-moving-premarket
Why F5 Shares Are Trading Higher By Over 1...
07/30/2024 09:50:34

celldex-announces-phase-2-results-for-barzolvolimab-in-chronic-inducible-urticaria-achieves-primary-endpoint-with-significant-complete-response-rates-in-both-dose-groups
Celldex Announces Phase 2 Results For Barz...
07/29/2024 20:10:05

First Large, Randomized, Placebo-Controlled Study To Demonstrate Success In CIndU; Plans Phase 3 Registration Development; Webc...

viasat--ast-spacemobile-are-among-top-6-mid-cap-stocks-that-shined-the-brightest-last-week-july-21-july-27-are-the-others-in-your-portfolio
ViaSat & AST SpaceMobile Are Among Top 6 M...
07/28/2024 18:17:42

Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%

analyst-expectations-for-celldex-therapeuticss-future
Analyst Expectations For Celldex Therapeut...
07/16/2024 19:01:15

hc-wainwright--co-reiterates-buy-on-celldex-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Cell...
07/16/2024 17:31:48

HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $80 ...

celldex-therapeutics-begins-global-phase-3-program-for-barzolvolimab-in-patients-with-chronic-spontaneous-urticaria
Celldex Therapeutics Begins Global Phase 3...
07/16/2024 12:03:30

cantor-fitzgerald-reiterates-overweight-on-celldex-therapeutics-maintains-67-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/18/2024 13:45:01

Cantor Fitzgerald analyst Kristen Kluska reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and maintains $67 p...

wolfe-research-initiates-coverage-on-celldex-therapeutics-with-outperform-rating
Wolfe Research Initiates Coverage On Celld...
06/11/2024 18:13:38

Wolfe Research analyst Andy Chen initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Outperform rating.

analyst-expectations-for-celldex-therapeuticss-future
Analyst Expectations For Celldex Therapeut...
06/03/2024 12:00:29

hc-wainwright--co-reiterates-buy-on-celldex-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Cell...
06/03/2024 11:15:10

HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $80 ...

celldex-therapeutics-reported--data-showing-barzolvolimab-improves-angioedema-at-12-weeks-in-phase-2-study-for-chronic-spontaneous-urticaria
Celldex Therapeutics Reported Data Showin...
06/02/2024 14:01:04

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema a...

hc-wainwright--co-reiterates-buy-on-celldex-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Cell...
05/15/2024 14:40:48

HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $80 ...

celldex-doses-first-patient-in-phase-2-study-of-barzolvolimab-in-prurigo-nodularis
Celldex Doses First Patient In Phase 2 Stu...
05/15/2024 12:02:22

unveiling-4-analyst-insights-on-celldex-therapeutics
Unveiling 4 Analyst Insights On Celldex Th...
05/07/2024 20:00:33

hc-wainwright--co-reiterates-buy-on-celldex-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Cell...
05/07/2024 10:55:07

HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $80 ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION